Skip to search formSkip to main contentSkip to account menu

Oncolytic HSV-1 rRp450

Known as: rRp450 
A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
2017
2017
Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors
2016
2016
Abstract B13: Injection of the viroimmunotherapeutic oncolytic herpes virus rRp450 increases survival of orthotopic mouse models of Group 3 medulloblastoma and atypical teratoid/rhabdoid tumors
Background: Both Group 3 medulloblastomas and atypical teratoid/ rhabdoid tumors (AT/RTs) are highly aggressive pediatric brain… 
Review
2013
Review
2013
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses… 
Highly Cited
2002
Highly Cited
2002
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene
Herpes simplex virus 1 (HSV‐1) infection of cancer cells results in viral replication with cell destruction and liberation of… 
2001
2001
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsible for bioconverting cyclophosphamide (CPA) into the… 
2001
2001
Advances in Brief Intraneoplastic Polymer-based Delivery of Cyclophosphamide for Intratumoral Bioconversion by a Replicating Oncolytic Viral Vector 1
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsible for bioconverting cyclophosphamide (CPA) into the… 
Highly Cited
1999
Highly Cited
1999
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Multimodal therapy is generally more effective than single-agent treatment for cancer. rRp450 is an engineered herpes simplex… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)